# Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

> **NCT03462004** · PHASE1 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 15 (actual)

## Conditions studied

- Ebola Virus Disease

## Interventions

- **BIOLOGICAL:** HPIV3/ΔHNF/EbovZ GP vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03462004
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-05
- **Primary completion:** 2019-03-15
- **Final completion:** 2019-03-15
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Cancel Enrollment due to Covid-19 Pandemic, Not restarted
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03462004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03462004, "Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03462004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*